BioSpace News Archive

As of December 31, 2017, Odonate had $198.1 million in cash, compared to $2.6 million as of December 31, 2016.

The novel system, which has been shown to significantly reduce the risk of stroke in the first three days after TAVR by more than 60 percent, has been adopted by 50 U.S. centers as part of its controlled rollout.

The solution integrates the novel extraction chemistry on the Hamilton Microlab STAR liquid handling platform to provide high through-put solution for applications such as biorepositories, genomics research and pharmacogenomics that require substantial amounts of DNA to be extracted from large-volume samples.

The Phase 3 program is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety global development program.

Actinic keratosis is a common skin condition that is induced through ultra-violet light damage, resulting in patches of thick, scaly, or crusty skin.

Ra Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 8,400,000 shares of its common stock at a public offering price of $6.00 per share, before underwriting discounts.

This expanded indication confirms Impella support as appropriate in patients with severe coronary artery disease, complex anatomy and extensive comorbidities, with or without depressed ejection fraction.

The Series B preferred stock issued in the public offering is convertible into shares of the company’s common stock at a conversion price of $2.00 per share.

On an adjusted basis, Oncobiologics had a net loss attributable to common stockholders for the three months ended December 31, 2017 of $5.0 million.

Scythian will ring the closing bell at the Nasdaq MarketSite in Times Square, New York City on February 22, 2018.